Literature DB >> 11791986

Short report: do intestinal nematodes increase the risk for multibacillary leprosy?

L M Diniz1, E Zandonade, R Dietze, F E Pereira, R Ribeiro-Rodrigues.   

Abstract

Intestinal helminths are known to subvert the host's immune response towards a Th2 response, which in turn may lead to both eosinophilia and high immunoglobulin E titers often associated with these parasites. Mycobacterium leprae infection may lead to different clinical and pathological forms. Multibacillary forms are associated with Th2 cytokines, whereas paucibacillary forms are associated with Th1 cytokines. We report a significantly higher frequency of intestinal helminthic infections in patients with the lepromatous form, a multibacillary form of leprosy (odds ratio, 2.99; 95% confidence interval, 1.82-4.95; P = 0.006) when compared with patients with paucibacillary leprosy or to a control group without leprosy. A direct correlation was also found between mycobacterial index and the frequency of intestinal helminths. Our results suggest that the presence of intestinal helminths may facilitate the establishment of M. leprae infection or the progression to more severe forms of leprosy.

Entities:  

Mesh:

Year:  2001        PMID: 11791986     DOI: 10.4269/ajtmh.2001.65.852

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  12 in total

1.  Intestinal helminth co-infection has a negative impact on both anti-Mycobacterium tuberculosis immunity and clinical response to tuberculosis therapy.

Authors:  T Resende Co; C S Hirsch; Z Toossi; R Dietze; R Ribeiro-Rodrigues
Journal:  Clin Exp Immunol       Date:  2007-01       Impact factor: 4.330

Review 2.  Recombinant Mycobacterium bovis BCG as an HIV vaccine vector.

Authors:  Rosamund Chapman; Gerald Chege; Enid Shephard; Helen Stutz; Anna-Lise Williamson
Journal:  Curr HIV Res       Date:  2010-06       Impact factor: 1.581

3.  Presence of intestinal helminths decreases T helper type 1 responses in tuberculoid leprosy patients and may increase the risk for multi-bacillary leprosy.

Authors:  L M Diniz; E F L Magalhães; F E L Pereira; R Dietze; R Ribeiro-Rodrigues
Journal:  Clin Exp Immunol       Date:  2010-04-09       Impact factor: 4.330

Review 4.  Interactions between worm infections and malaria.

Authors:  Mathieu Nacher
Journal:  Clin Rev Allergy Immunol       Date:  2004-04       Impact factor: 8.667

Review 5.  Immunological mechanisms by which concomitant helminth infections predispose to the development of human tuberculosis.

Authors:  Patricia Méndez-Samperio
Journal:  Korean J Parasitol       Date:  2012-11-26       Impact factor: 1.341

6.  Prevalence of intestinal parasitic infections among highland and lowland dwellers in Gamo area, South Ethiopia.

Authors:  Teklu Wegayehu; Tsegaye Tsalla; Belete Seifu; Takele Teklu
Journal:  BMC Public Health       Date:  2013-02-18       Impact factor: 3.295

7.  New insights in the pathogenesis and genetics of leprosy.

Authors:  Andrea Gulia; Isabella Fried; Cesare Massone
Journal:  F1000 Med Rep       Date:  2010-04-27

8.  Prevalence of intestinal parasitic infections and risk factors among schoolchildren at the University of Gondar Community School, Northwest Ethiopia: a cross-sectional study.

Authors:  Aschalew Gelaw; Belay Anagaw; Bethel Nigussie; Betrearon Silesh; Atnad Yirga; Meseret Alem; Mengistu Endris; Baye Gelaw
Journal:  BMC Public Health       Date:  2013-04-05       Impact factor: 3.295

9.  Schistosoma haematobium infection and Buruli ulcer.

Authors:  Janet T Scott; Roch C Johnson; Julia Aguiar; Martine Debacker; Luc Kestens; Augustin Guedenon; Bruno Gryseels; Françoise Portaels
Journal:  Emerg Infect Dis       Date:  2004-03       Impact factor: 6.883

10.  Interleukin-10-dependent down-regulation of interferon-gamma response to Leishmania by Mycobacterium leprae antigens during the clinical course of a coinfection.

Authors:  R B G Azeredo-Coutinho; D C S Matos; J A C Nery; C M Valete-Rosalino; S C F Mendonça
Journal:  Braz J Med Biol Res       Date:  2012-05-10       Impact factor: 2.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.